History
ToxiPharm Laboratories is a privately owned contract research organisation that was created in 2010 to respond to the increasing demand for customized study research projects. We started by tailoring research models that reproduced pathological diseases to study the efficacy and safety of new chemical entities. This required specific adjustments that could not be offered on a large scale production by big CRO’s.
Because no one is an expert in everything, ToxiPharm recruits expert research collaborators in specific disease models that matters to your projects to design, execute and interpret your study. The unique platform created by ToxiPharm Laboratories thus allows to bring years of expertise at the table to insure the quality of the results. Since then, there has been an enormous interest in the pharmaceutical industries to have tailored research design that best evaluate the new chemical entity in early drug development.
Over the years, ToxiPharm Laboratories has build an efficient network of specialized collaborators/ consultants with unique laboratory facilities. Now, ToxiPharm designs unmatched studies which answer very specific efficacy, safety or toxicology questions on drug development. Moreover, oversees experiments conducted in well established respective laboratories. ToxiPharm thus differs from the standard CRO by working with collaborators who possess years of experience and knowledge that are relevant to your specific requests.
Get in touch
ToxiPharm always tries to expand its services. Please write your request and we will customize a protocol to meet your needs.
Book an appointment ▸
Who we are
Partner
Charles E. Laurent
The Director of in vivo pharmacology at IPS Therapeutique is responsible for the identification of the experimental preclinical need, the development of the necessary in vivo pharmacological assays in efficacy or safety pharmacology studies, and the supervision of the conduct of the assays by IPST staff. Over the years, I have designed and completely validated half a dozen unique assays which are now routinely run at IPS Therapeutique and served for quantifying efficacy in preclinical drug candidates.
Education
UNIVERSITY OF MONTREAL
Ph.D., Pharmacology, 2001
PITTSBURGH MEDICINE UNIVERSITY
Postdoc, molecular biology, 2004
Activities & Affiliations
• ABCD Association, Member
• Pharmacology Association, Member-at-Large
• American Society for microbiology, Secretary
Publications
• New York, Tennessee, California
Partner
Dany Salvail
Director of Pharmacology at IPST, responsible for the management of scientific operations within a pre-clinical contract research organisation (CRO) specialized in cardiovascular safety and efficacy assessment.
More recently called upon to advise on early, pre-clinical drug development strategy, especially cardiac, vascular, and respiratory toxicity issues and mechanisms.
As a complement to IPST and exclusively meant to address non-cardiovascular safety and efficacy issues, ToxiPharm Inc. was founded as a CRO with a novel business model; to frame and facilitate industry-academia collaborations in applied Discovery and Safety Pharmacology.
Specialties: Pre-clinical cardiovascular efficacy, safety and toxicity, electrophysiology, regulatory safety pharmacology issues.
Education
UNIVERSITY OF SHERBROOKE
Faculty of Medicine, 1999
BISHOP'S UNIVERSITY
B.Sc, Biochemistry, 1995
Activities & Affiliations
• ABCD Association, Member
• Pharmacology Association, Member-at-Large
• American Society for microbiology, Secretary
Publications
• New York, Illinois, California